Oncologia

Revisão | Exames de imagem no câncer de próstata.

20 Jan, 2022 | 20:45h

Imaging of Prostate Cancer – Deutsches Ärzteblatt International

Conteúdos relacionados:

ASCO Guideline: Optimum Imaging Strategies for Advanced Prostate Cancer

RCT: MRI can cut overdiagnoses in prostate-cancer screening by half.

RCT: MRI-targeted biopsy safely reduces the need for biopsy in more than one-third of men at risk for prostate cancer

Meta-Analysis: Negative Predictive Value of MRI in the Detection of Clinically Significant Prostate Cancer

Study: MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis

Review: The Use of MRI and PET Imaging Studies for Prostate Cancer Management

Meta-Analysis: MRI plus Targeted Biopsy vs. Systematic Biopsy Alone for the Diagnosis of Prostate Cancer

Cochrane Review: MRI Pathway vs. Systematic Biopsy for Detecting Prostate Cancer

RCT: Inclusion of 18F-fluciclovine-PET/CT imaging to guide postprostatectomy salvage radiotherapy in patients with prostate cancer may improve survival free from biochemical recurrence or persistence.

Meta-analysis: Clinical Utility of MRI in the Decision-making Process Before Radical Prostatectomy

Research: Biparametric MRI (simpler, faster) May Be Used to Exclude Aggressive Disease and Avoid Unnecessary Biopsies in Men with Clinical Suspicion of Prostate Cancer

Research: MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis

Multiparametric MRI in the Detection of Clinically Significant Prostate Cancer

---

Diretriz ASCO | Tratamento do câncer de pulmão não pequenas células estágio III.

20 Jan, 2022 | 20:34h

Management of Stage III Non–Small-Cell Lung Cancer: ASCO Guideline – Journal of Clinical Oncology

---

Capecitabina adjuvante para câncer de mama de início precoce: resultados de um estudo randomizado da sobrevida geral de 15 anos.

20 Jan, 2022 | 20:32h

Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial – Journal of Clinical Oncology

---

Estudo randomizado | Paclitaxel e carboplatina são não inferiores a paclitaxel e ifosfamida em pacientes com carcinossarcoma de útero ou ovário.

20 Jan, 2022 | 20:31h

Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial – Journal of Clinical Oncology (link para o resumo – $ para o texto completo)

Comentário: Paclitaxel Plus Carboplatin Is Reportedly Non-Interior to Paclitaxel and Ifosfamide in Uterine Carcinosarcoma – Cancer Network

---

Estudo randomizado | Sirolimo com prednisolona vs. sirolimo em monoterapia para hemangiotelioma kaposiforme.

20 Jan, 2022 | 20:28h

Sirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma: a randomized clinical trial – Blood (link para o resumo – $ para o texto completo)

---

Inteligência artificial para diagnóstico de graduação de Gleason do câncer de próstata: o desafio PANDA.

20 Jan, 2022 | 16:06h

Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge – Nature Medicine

Comentário: Large international evaluation shows AI accurately diagnoses prostate cancer – Karolinska Institutet

 

Comentário de um dos autores no Twitter (fio – clique para saber mais)

Honored to be part of the recently published study in Nature Medicine on the global #AI competition PANDA as a member of the @Google team and an expert panel of 6 US and Canadian Uropathologists. Check out this thread for my 5 top takeaways 👇#pathology #PathTwitter

— Dr. Mahul Amin (@DrMahul) January 14, 2022

 

---

Estatísticas de câncer dos EUA, 2022.

20 Jan, 2022 | 16:05h

Cancer statistics, 2022 – CA: A Cancer Journal for Clinicians

---

Estudo randomizado | Nivolumabe com quimioterapia melhorou a sobrevida livre de progressão, mas não a sobrevida geral, em comparação com placebo e quimioterapia em pacientes com câncer gástrico ou gastresofágico avançado ou recorrente, HER2-negativo, não tratado e irressecável.

20 Jan, 2022 | 16:04h

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial – The Lancet Oncology (link para o resumo – $ para o texto completo)

---

Marcos do câncer: novas dimensões.

17 Jan, 2022 | 12:56h

Hallmarks of Cancer: New Dimensions – Cancer Discovery

 

Comentário no Twitter

Just published! We proudly present "Hallmarks of Cancer: New Dimensions" by Douglas Hanahan, the third update to the seminal series. https://t.co/bSer4maIjF @Ludwig_Cancer pic.twitter.com/k8S6OT3nuo

— Cancer Discovery (@CD_AACR) January 12, 2022

 

---

Achados preliminares de estudo randomizado mostraram resultados promissores de bloqueio duplo de PD-1 e HER2 no câncer gástrico HER2 positivo.

17 Jan, 2022 | 12:51h

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer – Nature

Comentário: KEYNOTE-811: Pembrolizumab combination as a potentially transformative treatment for HER2-positive gastric cancer – Vall d’Hebron University Hospital

 

Comentário no Twitter

Nature research paper: Combining immunotherapy with chemotherapy and targeted agents has the potential to improve the outcome of patients with advanced HER2-positive gastric tumours https://t.co/CNAgZObuTS pic.twitter.com/FWGwQzf4ze

— nature (@Nature) December 15, 2021

 

---